US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
HU196714B
(en)
|
1984-10-04 |
1989-01-30 |
Monsanto Co |
Process for producing non-aqueous composition comprising somatotropin
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
WO1991015516A2
(en)
|
1990-04-06 |
1991-10-17 |
Genelabs Incorporated |
Hepatitis c virus epitopes
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
DE4207363A1
(de)
|
1992-03-04 |
1993-09-09 |
Max Delbrueck Centrum |
Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6433159B1
(en)
|
1992-09-10 |
2002-08-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus associated diseases
|
EP0662157B1
(en)
|
1992-09-10 |
2001-06-20 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis c virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
DE69419244T2
(de)
|
1993-02-24 |
1999-10-14 |
Jui H Wang |
Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
EP0773029A4
(en)
|
1993-07-19 |
1997-09-03 |
Tokyo Tanabe Co |
HEPATITIS C VIRUS PROLIFERATION INHIBITOR
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
JP3786447B2
(ja)
|
1995-03-31 |
2006-06-14 |
エーザイ株式会社 |
C型肝炎の予防・治療剤
|
EP0835101B1
(en)
|
1995-06-27 |
2004-06-09 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
WO1997032018A2
(en)
|
1996-02-29 |
1997-09-04 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
GB9617177D0
(en)
|
1996-08-15 |
1996-09-25 |
Kvaerner H & G Offshore Ltd |
Downhole valve actuation
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
PL194025B1
(pl)
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
PT839525E
(pt)
|
1996-10-31 |
2004-10-29 |
Takeda Chemical Industries Ltd |
Preparacao de libertacao prolongada
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US6197350B1
(en)
|
1996-12-20 |
2001-03-06 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
GB9708611D0
(en)
|
1997-04-28 |
1997-06-18 |
Univ Cardiff |
Chemical compounds
|
CZ293248B6
(cs)
|
1997-06-30 |
2004-03-17 |
Merz Pharma Gmbh & Co. Kgaa |
1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi
|
ES2234144T3
(es)
|
1997-08-11 |
2005-06-16 |
Boehringer Ingelheim (Canada) Ltd. |
Analogos de peptidos inhibidores de la hepatitis c.
|
EA008609B1
(ru)
|
1998-02-25 |
2007-06-29 |
Эмори Юниверсити |
2'-фторнуклеозиды
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
GB9821058D0
(en)
|
1998-09-28 |
1998-11-18 |
Univ Cardiff |
Chemical compound
|
ATE241633T1
(de)
|
1999-02-12 |
2003-06-15 |
Glaxo Group Ltd |
Phosphoramidat-, mono-, di-, und triphosphatester von (1r, cis)-4-(6-amino-9h-purin-9-yl)-2- cyclopentene-1-methanol als antivirale mittel
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
WO2001032153A2
(en)
|
1999-11-04 |
2001-05-10 |
Shire Biochem Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
NZ521210A
(en)
|
2000-02-18 |
2004-11-26 |
Shire Biochem Inc |
Method for the treatment or prevention of flavivirus infections using nucleoside analogues
|
CN100457118C
(zh)
|
2000-04-13 |
2009-02-04 |
法玛塞特有限公司 |
用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
|
GB0009486D0
(en)
|
2000-04-17 |
2000-06-07 |
Univ Cardiff |
Chemical compounds
|
GB0011203D0
(en)
|
2000-05-09 |
2000-06-28 |
Univ Cardiff |
Chemical compounds
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
WO2002008251A2
(en)
|
2000-07-21 |
2002-01-31 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
BR0112666A
(pt)
|
2000-07-21 |
2003-06-10 |
Schering Corp |
Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
CN1133642C
(zh)
|
2000-10-09 |
2004-01-07 |
清华大学 |
核苷5’-硫代磷酰氨基酸酯化合物
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
JP3889708B2
(ja)
|
2000-11-20 |
2007-03-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎トリペプチド阻害剤
|
US6911428B2
(en)
|
2000-12-12 |
2005-06-28 |
Schering Corporation |
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
AU2002230764A1
(en)
|
2000-12-13 |
2002-06-24 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
WO2002048165A2
(en)
|
2000-12-15 |
2002-06-20 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
MY134070A
(en)
|
2001-01-22 |
2007-11-30 |
Isis Pharmaceuticals Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US6927291B2
(en)
|
2001-03-01 |
2005-08-09 |
Pharmasset, Ltd. |
Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides
|
WO2003070750A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
Rna interference mediated inhibition of hepatitis c virus
|
US20040209831A1
(en)
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
EP1404694A1
(en)
|
2001-06-21 |
2004-04-07 |
Glaxo Group Limited |
Nucleoside compounds in hcv
|
US7022323B2
(en)
|
2001-06-26 |
2006-04-04 |
Progenics Pharmaceuticals, Inc. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
JP2005504087A
(ja)
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
JP2005536440A
(ja)
|
2001-09-28 |
2005-12-02 |
イデニクス(ケイマン)リミテツド |
4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
JP2005527499A
(ja)
|
2002-02-13 |
2005-09-15 |
メルク エンド カムパニー インコーポレーテッド |
ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法
|
WO2003072757A2
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
EP1506000B9
(en)
|
2002-05-20 |
2011-08-31 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
WO2004043339A2
(en)
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
AU2003299519A1
(en)
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2003100017A2
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
AU2003251524A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Carbocyclic nucleoside analogs as RNA-antivirals
|
EP1551421A2
(en)
|
2002-06-21 |
2005-07-13 |
Merck & Co. Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
EP1572945A2
(en)
|
2002-06-27 |
2005-09-14 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
WO2004003000A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
|
EP2799442A1
(en)
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
EP1536804A4
(en)
|
2002-06-28 |
2007-10-31 |
Idenix Cayman Ltd |
2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
EP1556399A4
(en)
|
2002-07-16 |
2007-09-26 |
Merck & Co Inc |
NUCLEOSIDE DERIVATIVES AS RNA-DEPENDENT VIRAL RNA POLYMERASE INHIBITORS
|
AU2003256619A1
(en)
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
MXPA05006230A
(es)
|
2002-12-12 |
2005-09-20 |
Idenix Cayman Ltd |
Proceso para la produccion de nucleosidos ramificados-2'.
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
AR043006A1
(es)
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2005020884A2
(en)
|
2003-05-14 |
2005-03-10 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
ES2586668T3
(es)
|
2003-05-30 |
2016-10-18 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
KR20060026426A
(ko)
|
2003-06-19 |
2006-03-23 |
에프. 호프만-라 로슈 아게 |
4'-아지도 뉴클레오사이드 유도체의 제조 방법
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
US20050043266A1
(en)
|
2003-07-25 |
2005-02-24 |
Sumedha Jayasena |
Short interfering RNA as an antiviral agent for hepatitis C
|
KR20120010278A
(ko)
|
2003-10-10 |
2012-02-02 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
|
GB0401088D0
(en)
|
2004-01-19 |
2004-02-18 |
Univ Cardiff |
Phosphoramidate derivatives
|
ES2543834T3
(es)
|
2004-03-04 |
2015-08-24 |
K.U.Leuven Research & Development |
Fosfonato nucleósidos útiles como principios activos en composiciones farmacéuticas para el tratamiento de infecciones víricas y compuestos intermedios para su producción
|
WO2005123087A2
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
US20060040944A1
(en)
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
WO2006000085A1
(en)
|
2004-06-28 |
2006-01-05 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
EP1778251B1
(en)
|
2004-07-27 |
2011-04-13 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti hiv agents
|
DE602005015466D1
(de)
|
2004-08-23 |
2009-08-27 |
Hoffmann La Roche |
Antivirale 4'-azidonucleoside
|
CN101068828A
(zh)
|
2004-08-27 |
2007-11-07 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
|
WO2007001406A2
(en)
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
US20080280842A1
(en)
|
2004-10-21 |
2008-11-13 |
Merck & Co., Inc. |
Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
|
EP1827460A4
(en)
|
2004-12-09 |
2012-03-14 |
Univ Minnesota |
NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
|
WO2006093987A1
(en)
|
2005-02-28 |
2006-09-08 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
EP1898934A1
(en)
|
2005-03-09 |
2008-03-19 |
Idenix (Cayman) Limited |
Nucleosides with non-natural bases as anti-viral agents
|
WO2006116557A1
(en)
*
|
2005-04-25 |
2006-11-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
CA2606195C
(en)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
JP2009513564A
(ja)
|
2005-08-09 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
|
JP2009504677A
(ja)
|
2005-08-12 |
2009-02-05 |
メルク・エンド・カムパニー・インコーポレーテツド |
新規2’−c−メチル及び4’−c−メチルヌクレオシド誘導体
|
JP2009504704A
(ja)
|
2005-08-15 |
2009-02-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
|
AU2006294807B2
(en)
|
2005-09-26 |
2013-01-17 |
Gilead Pharmasset Llc |
Modified 4'-nucleosides as antiviral agents
|
CN101511375B
(zh)
|
2005-12-02 |
2012-09-05 |
耶鲁大学 |
L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
|
MY150667A
(en)
|
2005-12-09 |
2014-02-28 |
Gilead Pharmasset Llc |
Antiviral nucleosides
|
WO2007075876A2
(en)
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
JP2009526850A
(ja)
|
2006-02-14 |
2009-07-23 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
|
WO2007113159A1
(en)
|
2006-04-04 |
2007-10-11 |
F. Hoffmann-La Roche Ag |
3',5'-di-o-acylated nucleosides for hcv treatment
|
WO2008005542A2
(en)
|
2006-07-07 |
2008-01-10 |
Gilead Sciences, Inc., |
Antiviral phosphinate compounds
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
EP2361922B1
(en)
|
2006-10-10 |
2012-08-22 |
Janssen Products, L.P. |
Intermediate to HCV-Nucleoside Inhibitors
|
AU2007307057B2
(en)
|
2006-10-10 |
2011-09-15 |
F. Hoffmann La-Roche Ag |
Preparation of nucleosides ribofuranosyl pyrimidines
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
ATE478084T1
(de)
|
2006-12-11 |
2010-09-15 |
Hoffmann La Roche |
Verfahren zur herstellung von 4'- azidocytidinderivaten
|
AU2007338899A1
(en)
*
|
2006-12-20 |
2008-07-03 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2008083465A1
(en)
|
2007-01-08 |
2008-07-17 |
University Health Network |
Pyrimidine derivatives as anticancer agents
|
US8324179B2
(en)
|
2007-02-09 |
2012-12-04 |
Gilead Sciences, Inc. |
Nucleoside analogs for antiviral treatment
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
MX2009012433A
(es)
|
2007-05-14 |
2010-04-30 |
Rfs Pharma Llc |
Azido nucleosidos de purina para el tratamiento de infecciones virales.
|
US20090048189A1
(en)
|
2007-08-15 |
2009-02-19 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
US20090176732A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma Inc. |
Protected nucleotide analogs
|
KR101927905B1
(ko)
|
2008-04-03 |
2018-12-11 |
스프링 뱅크 파마슈티칼스, 인크. |
바이러스 감염증을 치료하기 위한 조성물 및 방법
|
PT2268642E
(pt)
|
2008-04-23 |
2015-06-02 |
Gilead Sciences Inc |
Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
GB0815968D0
(en)
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
EP3587434A1
(en)
|
2008-09-23 |
2020-01-01 |
Alnylam Pharmaceuticals Inc. |
Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
NZ593647A
(en)
*
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
MX2011006891A
(es)
|
2008-12-23 |
2011-10-06 |
Pharmasset Inc |
Fosforamidatos de nucleosidos.
|
KR20110120886A
(ko)
|
2009-01-09 |
2011-11-04 |
유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 |
바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CN102395590A
(zh)
|
2009-02-06 |
2012-03-28 |
Rfs制药公司 |
用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药
|
ES2453078T3
(es)
|
2009-02-10 |
2014-04-03 |
Gilead Sciences, Inc. |
Análogos de carba-nucleósido para tratamiento antiviral
|
JP2012521359A
(ja)
|
2009-03-20 |
2012-09-13 |
アリオス バイオファーマ インク. |
置換されたヌクレオシドアナログおよびヌクレオチドアナログ
|
US20100240604A1
(en)
|
2009-03-20 |
2010-09-23 |
Alios Biopharma, Inc. |
Protected nucleotide analogs
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
TW201107342A
(en)
|
2009-05-20 |
2011-03-01 |
Chimerix Inc |
Compounds, compositions and methods for treating viral infection
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
AU2010270715C1
(en)
|
2009-07-06 |
2016-03-17 |
Trilink Biotechnologies |
Chemically modified ligase cofactors, donors and acceptors
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US7973013B2
(en)
|
2009-09-21 |
2011-07-05 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US20100077085A1
(en)
|
2009-09-23 |
2010-03-25 |
Joseph Chyam Cohen |
Systems and method for configuring display resolution in a terminal server environment
|
BR112012007122A2
(pt)
|
2009-09-29 |
2016-07-12 |
Janssen Products Lp |
derivados de fosforamidatos de nucleosídeos
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
KR101840479B1
(ko)
|
2009-11-16 |
2018-03-20 |
유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 |
바이러스 감염 치료를 위한 2'―플루오로―6'―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
|
ES2437933T3
(es)
|
2010-01-28 |
2014-01-15 |
F. Hoffmann-La Roche Ag |
4'-azido-nucleósidos como compuestos anti-VHC
|
WO2011109037A1
(en)
|
2010-03-04 |
2011-09-09 |
Enanta Pharmaceuticals, Inc. |
Combination pharmaceutical agents as inhibitors of hcv replication
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
AU2011235112B2
(en)
|
2010-03-31 |
2015-07-09 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
MX2012011222A
(es)
*
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
TW201211047A
(en)
|
2010-06-10 |
2012-03-16 |
Gilead Sciences Inc |
Methods for treating HCV
|
JP5937073B2
(ja)
|
2010-07-19 |
2016-06-22 |
ギリード・サイエンシズ・インコーポレーテッド |
ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
EP2619215B1
(en)
|
2010-09-22 |
2018-09-05 |
Alios Biopharma, Inc. |
Azido nucleosides and nucleotide analogs
|
GEP20156313B
(en)
|
2010-09-22 |
2015-07-10 |
Alios Biopharma Inc |
Substituted nucleotide analogs
|
US20120070411A1
(en)
|
2010-09-22 |
2012-03-22 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012048013A2
(en)
|
2010-10-06 |
2012-04-12 |
Inhibitex, Inc. |
Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
|
PT2638054E
(pt)
|
2010-11-10 |
2015-03-02 |
Medivir Ab |
Fosforamidatos de nucleósidos de uracilo espirooxetano
|
EP2638053B1
(en)
|
2010-11-10 |
2016-08-31 |
Janssen Products, L.P. |
Uracyl spirooxetane nucleoside phosphoramidates
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
US20130273005A1
(en)
|
2010-12-20 |
2013-10-17 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
WO2012088155A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Alios Biopharma, Inc. |
Cyclic nucleotide analogs
|
US9351989B2
(en)
|
2010-12-29 |
2016-05-31 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
US9156874B2
(en)
|
2011-01-03 |
2015-10-13 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
US9095599B2
(en)
|
2011-01-03 |
2015-08-04 |
Nanjing Molecular Research, Inc. |
O-(substituted benzyl) phosphoramidate compounds and therapeutic use
|
WO2012125900A1
(en)
|
2011-03-16 |
2012-09-20 |
Enanta Pharmaceuticals, Inc. |
2'-allene-substituted nucleoside derivatives
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9150603B2
(en)
|
2011-04-13 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
|
MX2013011944A
(es)
*
|
2011-04-13 |
2014-05-07 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
|
BR112013026219A2
(pt)
|
2011-04-13 |
2016-07-26 |
Gilead Sciences Inc |
análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral
|
KR20140033446A
(ko)
|
2011-05-19 |
2014-03-18 |
알에프에스 파마 엘엘씨 |
바이러스 감염 치료용 퓨린 모노포스페이트 프로드럭
|
WO2013009737A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CN103987712B
(zh)
|
2011-07-19 |
2016-05-04 |
河南美泰宝生物制药有限公司 |
2’,3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8575119B2
(en)
|
2011-09-23 |
2013-11-05 |
Enanta Pharmaceuticals, Inc. |
2′-chloroacetylenyl substituted nucleoside derivatives
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013084165A1
(en)
|
2011-12-05 |
2013-06-13 |
Medivir Ab |
Hcv polymerase inhibitors
|
KR101687084B1
(ko)
|
2011-12-20 |
2016-12-15 |
리보사이언스 엘엘씨 |
Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
|
MX350809B
(es)
|
2011-12-20 |
2017-09-20 |
Riboscience Llc |
Derivados nucleósidos con sustitución 2',4'-difluoro-2'-metilo como inhibidores de la replicación del arn del vhc.
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
GEP201706723B
(en)
|
2012-10-08 |
2017-08-25 |
Idenix Pharmaceuticals Llk |
2'-chloro nucleoside analogs for hcv infection
|
US9242988B2
(en)
|
2012-10-17 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
AR092959A1
(es)
|
2012-10-17 |
2015-05-06 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
WO2014059902A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
WO2014124430A1
(en)
|
2013-02-11 |
2014-08-14 |
Emory University |
Nucleotide and nucleoside therapeutic compositions and uses related thereto
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014160484A1
(en)
|
2013-03-13 |
2014-10-02 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
CN103848876B
(zh)
|
2013-03-25 |
2016-05-11 |
安徽贝克联合制药有限公司 |
一种核苷磷酰胺前药及其制备方法和其应用
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2014204831A1
(en)
|
2013-06-18 |
2014-12-24 |
Merck Sharp & Dohme Corp. |
Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015077360A2
(en)
|
2013-11-20 |
2015-05-28 |
Idenix Pharmaceuticals, Inc. |
Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
|
EP3074411A2
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of liver cancer
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
CN103848877B
(zh)
|
2013-12-16 |
2016-08-24 |
安徽贝克联合制药有限公司 |
核苷环磷酸酯化合物及其制备方法和其应用
|
WO2015095305A1
(en)
|
2013-12-17 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
WO2015134780A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|